IMO, leronlimab has about a 90% chance of meeting stat sig, and about 10% chance of meeting only clinical sig. There is 0% for no significance because the DSMC would have stopped the trial for futility at interim. So with that being said, with the 10% chance of meeting only clinical sig, when the time comes, I hope NP will PR that even though the results are only clinical sig, Cytodyn is still in consideration for EUA and that Cytodyn is applying because it meets the "may help and does no harm" criteria. Also, the unmet need criteria is still in effect as many other drugs have failed trials and are changing endpoints.